Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, 8-K, regulatory
TL;DR
Monopar dropped an 8-K, likely standard disclosures. Keep an eye out for details.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on December 6, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. Specific details regarding material events or financial performance are not elaborated upon in the provided text, but the filing indicates a standard disclosure process.
Why It Matters
This 8-K filing indicates that Monopar Therapeutics is making required disclosures to the SEC, which is standard practice for publicly traded companies to keep investors informed.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative events.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- December 6, 2024 (date) — Date of earliest event reported
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What specific events are being disclosed in this 8-K filing?
The filing indicates it is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', but the provided text does not detail the specific events.
When was the earliest event reported in this filing?
The earliest event reported was on December 6, 2024.
What is the principal executive office address for Monopar Therapeutics?
The principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics?
The provided text does not explicitly state the trading symbol, though it mentions 'Securities registered pursuant to Section 12(b) of the Act'.
What is the state of incorporation for Monopar Therapeutics?
Monopar Therapeutics Inc. is incorporated in Delaware.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-06 08:00:22
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20241205_8k.htm (8-K) — 25KB
- ex_754335.htm (EX-99.1) — 11KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-036825.txt ( ) — 181KB
- mnpr-20241206.xsd (EX-101.SCH) — 3KB
- mnpr-20241206_def.xml (EX-101.DEF) — 12KB
- mnpr-20241206_lab.xml (EX-101.LAB) — 16KB
- mnpr-20241206_pre.xml (EX-101.PRE) — 12KB
- mnpr20241205_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that a first patient was dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated December 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: December 6, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer